Sou Hu Cai Jing·2025-05-14 00:56Group 1 - Shenzhen Sailu Medical Technology Co., Ltd. has completed A+ round financing led by Fosun Pharma, with participation from Weichi Investment and existing shareholder Shenzhen Capital Group [1] - The funds will be used for the registration of a national sequencing platform, capacity expansion, and global market development, reinforcing its position in the life sciences tools sector [1] - Founded in 2020, Sailu Medical is a national high-tech enterprise focusing on developing proprietary upstream sequencing platforms and has built a leading super-resolution spatial omics platform [1] Group 2 - The Salus Pro sequencer developed by Sailu Medical received NMPA Class III medical device registration in January 2025, becoming the first domestic device to cover all application scenarios based on reversible terminator sequencing [2] - The company has established a comprehensive R&D system covering optics, fluidics, chips, and reagents, aiming to become a global leader in life science tools [2] - The financing marks a new phase of strategic cooperation between Fosun Pharma and Sailu Medical, focusing on product development, supply chain integration, and global market expansion [2]